October 05, 2007
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
Principal Investigator
Co-Investigators
Stephen Goldring, MD
Jo Hannafin, MD, PhD
Whitney Johnson, BA
Jonathan Kassak, BS, MBA
Stephen Lyman, PhD
Lisa Mandl, MD, MPH
Robert Marx, MD, MSc
Madhu Mazumdar, PhD
Alvin Mushlin, MD, ScM
Renee Razzano, MA
Laura Robbins, MSW
Carolyn Thai, BA
Geoffrey H. Westrich, MD
Friedrich Boettner, MD
Mark P. Figgie, MD
Mathias P. Bostrom, MD
Michael M. Alexiades, MD
Phillip D. Wilson Jr., MD
Douglas E. Padgett, MD
Russell E. Windsor, MD
Alejandro Gonzalez Della Valle, MD
Steven B. Haas, MD
David J. Mayman, MD
Charles N. Cornell, MD
Susan Bloomberg
Jason Guardado
Jessica Ryu
Elizabeth Cody
John Rutledge
Kenneth Mathis, MD
Nadia Camille
Summary
We will enroll all THA patients who undergo surgery at HSS and consent to be in the study. We estimate this to be approximately 2600 patients a year, based on 2006 data. (2648 THA were performed at HSS in 2006). Patients will receive follow-up questionnaires at one year, two years, and five years after their surgery.
Inclusion/Exclusion Criteria
Patients 18 years or older undergoing total hip arthroplasty at HSS
Contact Information
Principal Investigator
Thomas Sculco, MD
212.606.2478
Research Coordinator
Carolyn Thai
212.774.2754
